Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20980862 | 0.95 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL20980937 | 0.89 | CD274 (0.31) | — | |
| SCHEMBL23713757 | 0.84 | — | — | |
| SCHEMBL21792999 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL24114465 | 0.79 | SLC29A1 (0.30) | — | |
| SCHEMBL22281744 | 0.76 | KDM4E (0.33) | ALDH1A1GAA | |
| SCHEMBL23713760 | 0.75 | — | — | |
| SCHEMBL24114555 | 0.74 | HRH3 (0.31) | — | |
| SCHEMBL22509507 | 0.74 | MEN1 (0.46) | ALDH1A1 | |
| SCHEMBL5585759 | 0.74 | S1PR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708326-B2 | Immunomodulator compounds | CHEMOCENTRYX, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220175746-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20210147356-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2021-05-20 | — | — | US | disclosed |
| WO-2020047035-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE PD-L1 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| US-10568874-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190282555-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. | 2019-05-09 | — | — | US | disclosed |
| WO-2019023575-A1 | IMMUNOMODULATOR COMPOUNDS | CHEMOCENTRYX, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135745-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | ALDH1A1 877/4885GAA 4148/4885 |
| US-11708326-B2 | Immunomodulator compounds | IL2, FCGRT, IFNG | ALDH1A1 877/4885GAA 4148/4885 |
| US-20190282555-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | ALDH1A1 302/4885GAA 4430/4885 |
| US-20220175746-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | ALDH1A1 302/4885GAA 4430/4885 |
| US-20210147356-A1 | IMMUNOMODULATOR COMPOUNDS | IL2, FCGRT, IFNG | ALDH1A1 877/4885GAA 4148/4885 |
| US-10568874-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | ALDH1A1 302/4885GAA 4430/4885 |
| US-11759458-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | ALDH1A1 302/4885GAA 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.